94 filings
Page 2 of 5
8-K
owkv6
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
5uxquq1z
7 Jun 23
Regulation FD Disclosure
6:00am
S-8
drtu04jnd
8 May 23
Registration of securities for employees
4:59pm
8-K
j6zvk6
8 May 23
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
4:25pm
EFFECT
qfrtz0q3wi
2 May 23
Notice of effectiveness
12:15am
POS EX
yz2n7xye9sypkhi3id
1 May 23
Additional exhibits for listing
4:05pm
ARS
1id76uq
28 Apr 23
Annual report to shareholders
6:18am
DEFA14A
8bweh s692tgul
28 Apr 23
Additional proxy soliciting materials
6:17am
8-K
ak5p5
28 Apr 23
Departure of Directors or Certain Officers
12:00am
8-K
9wjts6il gxc6sezz
10 Apr 23
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
4:15pm
POS AM
cxyq9m6
16 Mar 23
Prospectus update (post-effective amendment)
5:15pm
8-K
a68jmdnipksjfcd9s
16 Mar 23
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
4:15pm
POSASR
sso1x zyxyovbj1dv
15 Mar 23
Automatic shelf registration (post-effective amendment)
4:19pm
8-K
zuh8y
26 Jan 23
Goal is to report initial SC291 clinical data this year
4:16pm
8-K
5v4 h0n9s8tgpqz
26 Jan 23
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
4:16pm
8-K
jfnrza1dxkzkkckl
10 Jan 23
Regulation FD Disclosure
9:01am
8-K
2qybqyxz8zwf73x4ee
29 Nov 22
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
4:11pm